Form 4: Voyager Therapeutics SVP Granted 100,000 Stock Options

Voyager Therapeutics, Inc. granted its SVP and General Counsel, Gregory L. Shiferman, 100,000 stock options at an exercise price of $4.02 per share.

Summary

• Gregory L. Shiferman, SVP and General Counsel of Voyager Therapeutics, Inc. (VYGR), was granted 100,000 stock options.
• The options have an exercise price of $4.02 per share.
• The transaction date for the grant was January 6, 2026.
• The options were granted under the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan.
• The options have an expiration date of January 6, 2036.
• Vesting commences on the grant date (January 6, 2026) and occurs over four years: 1/4th of the shares vest on the one-year anniversary, and an additional 1/48th vest at the end of each successive one-month period thereafter, subject to continued employment.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is a positive for aligning management incentives with shareholder interests, but it is a routine compensation event and does not reflect new operational or financial performance.

Positives

• The grant of stock options aligns the interests of the SVP and General Counsel with those of the shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice for executive retention and motivation in the biotechnology sector.

Future Outlook

The vesting schedule indicates that the options will become exercisable over a four-year period, contingent on the reporting person's continued service, providing a long-term incentive structure.

Industry Context

The grant of stock options to a senior executive is a common practice within the biotechnology industry, serving as a key component of executive compensation packages designed to attract, retain, and motivate talent by aligning their financial interests with the long-term performance of the company.

Comparison to Industry Standards

• Equity grants, such as stock options, are a standard form of executive compensation across the biotechnology and pharmaceutical sectors, similar to practices observed at peer companies.
• The four-year vesting schedule is typical for executive equity awards, aiming to foster long-term commitment and performance alignment with shareholder value creation.

Corporate Governance

Related Party Transactions

• The grant of stock options to Gregory L. Shiferman, an SVP and General Counsel, constitutes a related party transaction between the company and a key executive.

Stakeholder Impact

• Shareholders: The grant aims to align the executive's long-term interests with shareholder value creation, potentially leading to improved company performance. However, it also represents potential future dilution upon exercise.
• Employees: The grant serves as an example of executive compensation practices, potentially influencing overall compensation strategies and morale.

Next Steps

• The stock options will vest over the next four years, with the first quarter vesting on January 6, 2027, and subsequent monthly vesting thereafter, subject to continued employment.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (stock option grant) and does not contain new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It is a standard insider transaction that aligns executive incentives but does not fundamentally alter the investment thesis.

Keywords

Voyager Therapeutics, VYGR, Stock Options, Executive Compensation, Insider Transaction, Form 4, Equity Grant, Biotechnology